Egetis Therapeutics appoints Yilmaz Mahshid as new CFO

April 19, 2021

Stockholm, Sweden, April 19, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Yilmaz Mahshid, PhD, has been appointed Chief Financial Officer (CFO), joining in the second quarter of 2021. He will be part of the company’s management team and report to the CEO.

Yilmaz has experience from different senior positions in the life science sector, including Investment Manager & Controller at Industrifonden, and CFO at PledPharma between 2017 and 2020, as well as healthcare analyst at Pareto Securities and Öhman Fondkommission. Prior to joining Egetis Therapeutics, Yilmaz was CEO of the listed biotech company Medivir.

Yilmaz also has a solid academic background with a PhD from the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm.

He is taking over from Marie-Louise Alamaa, who joined as interim CFO in June 2020.

"We are pleased to welcome Yilmaz to Egetis. His extensive experience and knowledge in financial management, business development, investor relations and medical science makes him ideal in the role of CFO at Egetis, and I look forward to work with Yilmaz again. I also want to take this opportunity to thank Marie-Louise for her hard and diligent work as an interim CFO. Her drive, experience and significant knowledge within the field of finance was instrumental during the integration of Rare Thyroid Therapeutics (RTT) and the formation of Egetis", said Nicklas Westerholm, CEO of Egetis Therapeutics.

"It is going to be great to work with Nicklas and his team again and contribute to Egetis continued work to create value for its shareholders and all the patients who could benefit from the company's late-stage portfolio of innovative orphan drug candidates in rare diseases," said Yilmaz Mahshid.

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated in Dec 2020 with the first patient dosed and interim results are expected in 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that PledOx did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see http:// www.egetis.com/

Egetis Therapeutics appoints Yilmaz Mahshid as new CFO

Contact us